{"prompt": "['OSTPDL1', 'Page 49 of 60', 'Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions', 'when they are clearly defined and surrounded by aerated lung. However,', 'CT is preferable.', 'Conventional CT and MRI: This guideline has defined measurability of', 'lesions on CT scan based on the assumption that CT slice thickness is 5', 'mm or less. If CT scans have slice thickness greater than 5 mm, the', 'minimum size for a measurable lesion should be twice the slice', 'thickness. MRI is also acceptable in certain situations (e.g. for body', 'scans). Ideally, the same type of scanner should be used and the image', 'acquisition protocol should be followed as closely as possible to prior', 'scans.', 'PET-CT: At present, the low dose or attenuation correction CT portion of', 'a combined PET-CT is not always of optimal diagnostic CT quality for use', 'with RECIST measurements. However, if the site can document that the', 'CT performed as part of a PET-CT is of identical diagnostic quality to a', 'diagnostic CT (with IV and oral contrast), then the CT portion of the PET-', 'CT can be used for RECIST measurements and can be used', 'interchangeably with conventional CT in accurately measuring cancer', 'lesions over time. Note, however, that the PET portion of the CT', 'introduces additional data which may bias an investigator if it is not', 'routinely or serially performed.', 'Tumor markers: Tumor markers alone cannot be used to assess', 'response. If markers are initially above the upper normal limit, they must', 'normalize for a patient to be considered in complete clinical response.', 'Cytology, histology: These techniques can be used to differentiate', 'between partial responses (PR) and complete responses (CR) in rare cases', '(e.g., residual lesions in tumor types, such as germ cell tumors, where', 'known residual benign tumors can remain). Cytology should be obtained', 'if an effusion appears or worsens during treatment when the measurable', 'tumor has met criteria for response or stable disease.', '18F-FDG PET/PET-CT: While 18F-FDG PET/PET-CT response assessments', 'need additional study, it is sometimes reasonable to incorporate the use', 'of 18F-FDG PET/PET-CT scanning to complement CT scanning in', \"assessment of progression (particularly possible 'new' disease).\", 'New lesions on the basis of 18F-FDG PET/PET-CT imaging can be', 'identified according to the following algorithm:', 'a. Negative 18F-FDG PET/PET-CT at baseline, with a positive 18F-FDG', 'PET/PET-CT at follow-up is a sign of PD based on a new lesion.', 'b. No 18F-FDG PET/PET-CT at baseline and a positive 18F-FDG', 'PET/PET-CT at follow-up: If the positive 18F-FDG PET/PET-CT at', 'follow-up corresponds to a new site of disease confirmed by CT,', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 50 of 60', 'this is PD. If the positive 18F-FDG PET/PET-CT at follow-up is not', 'confirmed as a new site of disease on CT, additional follow-up CT', 'scans are needed to determine if there is truly progression', 'occurring at that site (if so, the date of PD will be the date of the', 'initial abnormal 18F-FDG PET/PET-CT scan). If the positive 18F-FDG', 'PET/PET-CT at follow-up corresponds to a pre-existing site of', 'disease on CT that is not progressing on the basis of the anatomic', 'images, this is not PD.', \"Note: A 'positive' 18F-FDG PET/PET-CT scan lesion means one that is FDG\", 'avid with an uptake greater than twice that of the surrounding tissue on', 'the attenuation corrected image.', '9.2', 'Response Criteria for Patients with Solid Tumor and Measurable', 'Disease', '9.2.1 Evaluation of Target Lesions', 'Complete response (CR): Disappearance of all target and non-target', 'lesions. Any pathological lymph nodes (whether target or non-target)', 'must have reduction in short axis to <10 mm. If immunocytology is', 'available, no disease must be detected by that methodology.', 'Partial response (PR): At least a 30% decrease in the sum of the diameters', 'of target lesions, taking as reference the baseline sum diameters.', 'Progressive disease (PD): At least a 20% increase in the sum of the', 'diameters of target lesions, taking as reference the smallest sum on study', '(this includes the baseline sum if that is the smallest on study). In addition', 'to the relative increase of 20%, the sum must also demonstrate an absolute', 'increase of at least 5 mm. (Note: the appearance of one or more new', 'lesions is also considered progressions). Note: in presence of SD or PR in', 'target disease but unequivocal progression in non-target or non-', 'measurable disease, the patient has PD if there is an overall level of', 'substantial worsening in non-target disease such that the overall tumor', 'burden has increased sufficiently to merit discontinuation of therapy.', 'Stable disease (SD): Insufficient shrinkage to qualify for PR or insufficient', 'increase to qualify for PD, taking as reference the smallest sum diameters', 'while on study.', '9.2.2 Evaluation of Non-Target Lesions', 'Complete response (CR): Disappearance of all non-target lesions and', 'normalization of tumor marker level. All lymph nodes must be non-', 'pathological in size (<10 mm short axis)', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}